Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.77 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7446920 | 1.00 | AGTR1 (0.77) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9424465 | 0.96 | AGTR1 (0.72) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9424461 | 0.96 | AGTR1 (0.72) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9424580 | 0.94 | AGTR1 (0.68) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9424588 | 0.94 | AGTR1 (0.68) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9424507 | 0.92 | AGTR1 (0.68) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9424499 | 0.92 | AGTR1 (0.68) | AGTR1ABCC3ABCC2 | |
| SCHEMBL682668 | 0.92 | AGTR1 (0.75) | AGTR1ABCC3ABCC2 | |
| SCHEMBL10441830 | 0.91 | AGTR1 (0.72) | AGTR1ABCC3ABCC2 | |
| SCHEMBL10441829 | 0.91 | AGTR1 (0.72) | AGTR1ABCC3ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5312828-A | Substituted imidazoles having angiotensin II receptor blocking activity | SMITHKLINE BEECHAM CORPORATION A CORP. OF PENNSYLVANIA | 1994-05-17 | — | — | US | claimed |
| EP-0724387-B1 | ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | SMITHKLINE BEECHAM P.1.C. | 2002-09-19 | — | — | US | disclosed |
| US-20020086893-A1 | Imidazole based angiotensin II receptor antagonist for treating haemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2002-07-04 | — | — | US | disclosed |
| US-20020055490-A1 | Improving cognitive function in a mammal which comprises administering an angiotensin TI receptor antagonist. | SMITHKLINE BEECHAM P.L.C. | 2002-05-09 | — | — | US | disclosed |
| US-20020006949-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2002-01-17 | — | — | US | disclosed |
| US-20010016594-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2001-08-23 | — | — | US | disclosed |
| US-6034114-A | ADMINISTERING ANGIOTENSIN RECEPTOR ANTAGONIST FOR VENTRICULAR HYPERTROPY REGRESSION | SMITHKLINE BEECHAM PLC (GB) | 2000-03-07 | — | — | US | disclosed |
| US-6025380-A | ANGIOTENSIN II RECEPTOR ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF MACULAR DEGENERATION. | SMITHKLINE BEECHAM PLC (GB) | 2000-02-15 | — | — | US | disclosed |
| US-5656650-A | TREATING HYPERTENSION | SMITHKLINE BEECHAM CORP. | 1997-08-12 | — | — | US | disclosed |
| US-5312828-A | Substituted imidazoles having angiotensin II receptor blocking activity | SMITHKLINE BEECHAM CORPORATION A CORP. OF PENNSYLVANIA | 1994-05-17 | — | — | US | disclosed |
| EP-0565634-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-20 | — | — | EP | disclosed |
| WO-1993006828-A1 | MEDICAMENT FOR THE TREATMENT OF ANXIETY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
| WO-1992010097-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | AGTR2, AGTR1, AGT | AGTR1 2/4885ABCC3 1102/4885ABCC2 523/4885 |
| US-20020055490-A1 | Improving cognitive function in a mammal which comprises administering an angiotensin TI receptor antagonist. | AGTR1, AGTR2, AGT | AGTR1 1/4885ABCC3 3247/4885ABCC2 2578/4885 |
| US-20020086893-A1 | Imidazole based angiotensin II receptor antagonist for treating haemorrhagic stroke | AGTR2, AGTR1, VIPR2 | AGTR1 2/4885ABCC3 3754/4885ABCC2 2325/4885 |
| US-20010016594-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR1 2/4885ABCC3 712/4885ABCC2 464/4885 |
| US-20020006949-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR1 2/4885ABCC3 860/4885ABCC2 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.